One key molecular determinant of tumour cell response to PARP inhibition is the ability to localise the DNA recombinase RAD51 to the site of DNA damage, a critical event in HR repair that can be monitored by the immunodetection of DNA damage induced RAD51 foci [3, 19]. Here, RAD51 is linked to neoplasm.